K. Rene Ward
Associate Director, Public Relations and Internal Communications
3902 Gene Field Road
St. Joseph, Missouri 64506
Leader in mastitis prevention and control recognized by NMC and Boehringer Ingelheim Vetmedica, Inc., Prevention Works
Ken Leslie, Professor Emeritus at the University of Guelph was the recipient of the first-ever National Mastitis Council (NMC) Award of Excellence for Mastitis Prevention and Control. The award was sponsored and presented by Prevention Works from Boehringer Ingelheim Vetmedica, Inc. and will be awarded annually to an active NMC member for sustained contribution to mastitis prevention and control through research, extension or education, clinical practice, or service to producers.
Professor Leslie is a well-known leader in milk quality research and education. His research spans high-impact work on use of SCC for mastitis diagnosis and monitoring, the impacts of an industry level SCC penalty program, published teat dip efficacy studies, and management of the drying-off process, just to name a few. Professor Leslie has advised or mentored over 70 graduate students and published over 170 peer reviewed papers in addition to a major textbook. Leslie enthusiastically championed the NMC 10 Point Plan for udder health and served on the organization’s executive committee.
Dr. Leslie is regarded around the world for his practical approach to research on how it translates to the farm. Cornell’s Ynte Schukken, DVM, PhD and Director at Quality Milk Production Services says, “Without a doubt, Dr. Leslie is among the most influential scholars in our field of udder health and milk quality.”
For more information about Boehringer Ingelheim Vetmedica, Inc., and their approach to cow health, Prevention Works, visit www.BIVIPreventionWorks.com.
Boehringer Ingelheim Vetmedica, Inc. (St. Joseph, MO), is a subsidiary of Boehringer Ingelheim Corporation based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For Boehringer Ingelheim—and its employees—carrying a good share of social responsibility is an important component in its business culture. Both global commitments in social projects and properly caring for all its employees are included. Respect, equal opportunity, and the balance of career and family life form the basis for mutual cooperation. And, environmental protection and sustainability are always the main focus during any of Boehringer Ingelheim’s undertakings.
In 2010, Boehringer Ingelheim posted net sales of approximately $16.7 billion (about 12.6 billion euro) while spending almost 24% of net sales in its largest business segment, Prescription Medicines, on research and development.
For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.